In the LIBRETTO-001 and ARROW clinical trials, in the arms of patients with treatment-naive RET-mutant MTC who received selpercatinib or pralsetinib, ORRs were 73% (95% CI, 62–82) and 71% (95% CI, 48–89), respectively, suggesting that these RET-targeted inhibitors might have a therapeutic advantage over available first-line MTKIs in the RET-altered population (53, 54). This evidence concerns the gene RET and medullary thyroid gland carcinoma.